At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 101 enrolled
Drug / intervention
PUL-042 Inhalation Solution +1 moredrug
Likely dose
PUL-042 Inhalation Solution 20.3 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
In Brief
A Phase 2 clinical trial evaluating PUL-042 Inhalation Solution and Placebo for COVID-19. Completed, enrolled 101 participants across 11 sites.
Detailed Summary
Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartJun 2020
Primary CompletionJul 2021
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartJun 16, 2020
Primary CompletionJul 2, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.3 years ago
Interventions
PUL-042 Inhalation Solutiondrug
20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
Placebodrug
Sterile saline for inhalation